


TIDES® Agenda-at-a-Glance

Sunday, April 25, 2010

9:00 am - 1:00 pm	Course #1: Current Topics in Oligonucleotide Manufacturing		Course #2: Bioanalytical Methods for the Determination of Therapeutic Oligonucleotides	
2:00 pm - 6:00 pm	Course #3: Current Topics in the Analysis of Oligonucleotides in Support of Drug Development	Course #4: Managing Analytical Development and Quality Control for Peptides	Course #5: Oligonucleotide Lead Discovery and Candidate Selection	
6:00 pm - 7:00 pm	Welcoming Reception for Course Attendees Sponsored by Avecia OligoMedicines and Alnylam			

Monday, April 26, 2010

Exhibit Hall/Poster Hours: 5:15 pm - 6:45 pm

8:30 am - 11:00 am	Keynote Presentations: Open to TIDES® and Oligo Therapeutics Discovery Delegates Synthetic Biologics: A New Class of Drugs for "Undruggable" Targets, Gregory L. Verdine, Ph.D., <i>Erving Professor of Chemistry, Harvard University</i> RNAi: Developing a New Therapeutic Platform, John Maraganore, Ph.D., <i>Chief Executive Officer, Alnylam Pharmaceuticals, Inc.</i> Non-Coding RNAs as Drug Targets, Claes R. Wahlestedt, M.D., Ph.D., <i>Professor, Director of Neuroscience Discovery, The Scripps Research Institute - Florida</i>			
11:30 am - 12:30 pm	TIDES Main Conference Featured Presentations Deal Trends in Nucleic Acid Based Therapeutics: A Look at Past Deals and Thoughts on the Future Philip McGurk, Ph.D., <i>Senior Director, Business Development, Pfizer Inc.</i> Update on Peptide Therapeutics Market Outlook Janice M. Reichert, Ph.D., <i>Senior Research Fellow, Tufts Center for the Study of Drug Development;</i> <i>Editor-in-Chief, mAbs, Landes Biosciences</i>			Oligonucleotide Therapeutics Discovery Conference What Are We Looking for from Oligonucleotide Therapeutics? Preclinical Chemical Modifications to Improve Drug-Like Properties (Session time: 11:30 am - 1:05 pm. Lunch on your own: 1:05 pm - 2:15 pm)
12:00 pm - 4:00 pm	Site Tour to Avecia OligoMedicines			
12:30 pm - 2:00 pm	Lunch on your own			
	Oligonucleotides	Peptides	Break-Out Discussion Sessions	
2:00 pm - 5:15 pm	Regulatory Updates for Oligonucleotides and Peptides		Late-Breaking Industry Issues	
5:15 pm - 6:45 pm	Networking Cocktail Reception, Opening of Poster and Exhibit Hall			

Tuesday, April 27, 2010

Exhibit Hall/Poster Hours: 9:30 am - 6:15 pm

	Oligonucleotides	Peptides	Break-Out Discussion Sessions	Applications of Nucleic Acids Technologies for Molecular Diagnostics	Oligonucleotide Therapeutics Discovery Conference
8:00 am - 9:30 am	Innovation Showcase 9:30 <i>Technology Workshop Sponsored by TransPharma Medical</i>		Regulatory Updates Follow up Discussions 8:00 - 8:45 Oligos 8:45 - 9:30 Peptides	Regulatory Pathways and Quality Strategies Keynote Presentations: Commercialization of IVDs Labeled for Research Use Only or Investigational Use Only Elizabeth Mansfield, Ph.D., <i>Director for Personalized Medicine, OIVD, CDRH, US FDA</i> Challenges in Drug and Diagnostic Co-Development – A Diagnostic Perspective William Pignato, Global Head, Regulatory Affairs, Novartis Molecular Diagnostics	Overcoming Cellular Barriers to siRNA Delivery Understanding Preclinical Toxicology of Oligonucleotides
10:15 am - 12:30 pm	CMC: Manufacturing and Analysis 11:30 <i>Technology Workshop Sponsored by Girindus America Inc. Member of Solvay Organics</i>	CMC: Manufacturing and Analysis	Topics to be announced		
12:30 pm - 1:45 pm	Networking Luncheon, Exhibit and Poster Viewing in Exhibit Hall sponsored by Lonza				
1:45 pm - 5:15 pm	CMC: Manufacturing and Analysis 3:45 <i>Technology Workshop Sponsored by Agilent Technologies</i>	CMC: Manufacturing and Analysis 2:15 <i>Technology Workshop Sponsored by Bruker Daltonics</i>	Topics to be announced	Manufacturing and Business Considerations for Successful Launch in Clinical Market	Preclinical/Clinical Case Studies
5:15 pm - 6:15 pm	Networking Cocktail Reception, Exhibit and Dedicated Poster Viewing				

Wednesday, April 28, 2010

Exhibit Hall/Poster Hours: 9:45 am - 1:30 pm

	Oligonucleotides	Peptides	Break-Out Discussion Sessions	Applications of Nucleic Acids Technologies for Molecular Diagnostics	Oligonucleotide Therapeutics Discovery Conference
8:00 am - 9:45 am	Formulation and Delivery	Formulation and Delivery	Follow Up Discussion to Oligo CMC Session	Analytical Methods and Validation	Formulation and Delivery <i>Shared w/TIDES® Oligo Track</i>
10:15 am - 12:15 pm	Formulation and Delivery	Formulation and Delivery	10:15 Applications of Mass Spectrometry to Synthetic Oligonucleotides 11:15 Intellectual Property Issues	Analytical Methods and Validation (continued) New Technologies	Formulation and Delivery <i>Shared w/TIDES® Oligo Track</i>
12:15 pm - 1:30 pm	Networking Luncheon, Final Opportunity for Exhibit and Poster Viewing in Exhibit Hall				
1:30 pm - 4:30 pm	Site Tour to Alnylam Pharmaceuticals				
1:30 pm - 5:15 pm	Updates on Compounds in Preclinical and Clinical Development	Updates on Compounds in Preclinical and Clinical Development	1:30 pm - 3:00 pm Peptide Impurities	New Technologies	Updates on Compounds in Preclinical and Clinical Development <i>Shared w/TIDES® Oligo Track</i>

Visit www.IBCLifeSciences.com/TIDES for up-to-date information on this event